{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-064341","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.021379+00:00","generated_at":"2026-06-08T01:16:03.972153+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CRISPR/VERTEX get UK conditional approval for CASGEVY in sickle cell & beta thalassemia","bullets":["CASGEVY (exagamglogene autotemcel) received conditional marketing authorization from UK MHRA.","Approved for patients 12+ with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.","Authorization requires no human leukocyte antigen matched related donor; valid for one year, renewable annually.","CRISPR and partner Vertex jointly developed the CRISPR/Cas9 gene-edited therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-064341","json":"https://secwatch.observer/filing/0000950170-23-064341.json","markdown":"https://secwatch.observer/filing/0000950170-23-064341.md","text":"https://secwatch.observer/filing/0000950170-23-064341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023064341/0000950170-23-064341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023064341/crsp-20231115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T01:16:03.972153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}